The in vitro antimicrobial activity of two new aryl-fluoroquinolone antibiotics, A-56619 and A-56620, was compared with those of norfloxacin and several other antibiotics against 448 bacterial isolates. A-56620 was the most active agent tested. The usual 90% MIC of A-56620 was .2 ,ug/ml, except for enterococci, gentamicinresistant Serratia marcescens, and gentamicin-resistant Pseudomonas aeruginosa, for which the 90% MIC was 4 Fg/ml. A-56619 and porfloxacin were generally severalfold less active than A-56620. Cross resistance was observed between the quinolope antibiotics and other unrelated antibiotic classes. Antimicrob. Agents Chemother., abstr. no. 77, 1984). In this study, the antimicrobial spectrum of potency of A-56619 and A-56620 were studied further and compared those of with norfloxacin and several broad-spectrum cephalosporins, penicillins, and other relevant antimicrobial agents.
A-56619 and A-56620 are two recently developed arylfluoroquinolone antimicrobials (D. T 77, 1984) . In this study, the antimicrobial spectrum of potency of A-56619 and A-56620 were studied further and compared those of with norfloxacin and several broad-spectrum cephalosporins, penicillins, and other relevant antimicrobial agents.
Antimicrobial compounds of known potency were provided as follows: A-56619 and A-56620 (Abbott Laboratories, North Chicago, Ill.); norfloxacin ( The comparative in vitro antimicrobial activity for A-56619, A-56620, and the other agents evaluated is presented in Table 1. A-56619 and A-56620 had similar activity against grampositive cocci. Both antimicrobial agents were more active than norfloxacin against methicillin-resistant Staphylococcus aureus, while A-56620 was more active against the enterococci and methicillin-susceptible Staphylococcus aureus. A-56619 and'A-56620 were generally more active than the other agents tested against the gram-positive cocci. Only ampicillin was more active than A-56619 and A-56620 against the enterococci and vancomycin was of about equal activity against methicillin-resistant Staphylococcus aureus.
For the gentamicin-susceptible members of the family Enterobacteriaceae, cefotaxime was generally the most active beta-lactam agent, with an MIC for 90% of strains tested (MICgo) of .0.25 ,ug/ml for all species tested, except Providencia spp., Citrobacter freundii, Enterobacter sp., and Citrobacter diversus. A-56620 was the most active quinolone carboxylic acid tested, with MIC90s ranging from 0.25 to 1.0 ,ug/ml for most of these same bacteria. However,
A-56620 did demonstrate exceptional potency against Escherichia coli, Citrobacter diversus, Salmonella enteritis, and Shigella sonnei. Norfloxacin was slightly more active than A-56620 against Serratia marcescens and Proteus mirabilis. A-56619 was generally two-to fourfold less active than A-56620 against these Enterobacteriaceae and was less active than norfloxacin against Aeromonas hydrophilia, Citrobacter diversus, Citrobacter freundii, Morganella morganii, Proteus mirabilis, and Serratia marcescens.
The quinolone carboxylic acids showed substantially diminished activity against gentamicin-resistant strains of Escherichia coli, Serratia marcescens, and Klebsiella pneu-ANTIMICROB. AGENTS CHEMOTHER. A-56620 and norfloxacin showed similar activity against carbenicillin-susceptible and -resistant strains of Pseudomonas aeruginosa (MIC90, 0.5 to 2 ,ug/ml), while A-56619 was severalfold less active. Gentamicin-resistant strains of Pseudomonas aeruginosa were at least fourfold less susceptible to A-56619, A-56620, and norfloxacin than were the gentamicin-sensitive strains. A-56620 and A-56619 were more active than norfloxacin and the beta-lactam antibiotics against both gentamicin-susceptible and -resistant Acinetobacter spp.
A-56620 and A-56619 were demonstrated to possess a broad spectrum of antimicrobial activity against staphylococci, enterococci, the Enterobacteriaceae, and Pseudomonas aeruginosa. A-56620 appeared to be the more potent of these two compounds. A-56620 was more active than norfloxacin against gentamicin-susceptible and -resistant Acinetobacter spp., Citrobacter diversus, ampicillin-sensitive Escherichia coli, gentamicin-resistant Kiebsiella pneumoniae, Proteus vulgaris, and Providencia spp. However, norfloxacin was more active against gentamicin-resistant Serratia marcescens and Proteus mirabilis. A-56620 and norfloxacin showed similar activity against Pseudomonas aeruginosa. Against many of the Enterobacteriaceae, cefotaxime showed comparable activity to the quinolone carboxylic acids that were evaluated.
It has been reported previously that the quinolone carboxylic acid derivatives are relatively less active when tested against bacterial isolates with an underlying resistance to certain beta-lactams and amikacin (2, (4) (5) (6) . Many of our gentamicin-resistant strains of Acinetobacter sp., Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens were also relatively or completely resistant to piperacillin and trimethoprim. Our data support the concept that cross resistance does exist between the quinolone antibiotics and other unrelated antibiotic classes. It was not clear, however, which resistant antibiotic class was most predictive of relative quinolone resistance.
The results of this study show that A-56620 and A-56619 possess a spectrum of activity which encompasses many clinically relevant bacterial pathogens. Further clinical study is warranted to determine their therapeutic role.
